Afyren SA
2.30
EUR
+0.00
(-0.22%)
ISIN
FR0014005AC9
Return %
Stock
S&P 500
1Y
7.48
14.20
3Y
-38.50
81.12
5Y
-71.32
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Nicolas Sordet
- Full Time Employees
- 149
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 9-11 rue Gutenberg Clermont-Ferrand ARA France 63100
- IPO Date
- Oct 1, 2021
- Website
- afyren.com
- Similar Companies
- Business
- Afyren SAS Afyren SAS (ALAFY.PA) is a green chemistry company that develops and produces biobased, low-carbon organic acids through proprietary fermentation technology using non-food agricultural biomass co-products, enabling industries to replace petroleum-sourced ingredients in a circular economy model. The company manufactures a family of seven 100% biobased carboxylic acids containing two to six carbon atoms via its patented AFYNERIE technology, achieving high purity levels exceeding 99% for select applications; these include acetic acid for flavors, fragrances, preservation, and cleaning products; propionic acid as a mold inhibitor in food, bakery, and animal feed; butyric acid for animal nutrition, pharmaceuticals, and cellulose acetate butyrate; isobutyric acid for cosmetics, perfumes, and creamy-fruity flavorings; valeric acid for synthetic lubricants in refrigeration, air conditioning, and aeronautics turbines; isovaleric acid for nut, coffee, cheese, and fruit flavors; and caproic acid for heat management lubricants in electric vehicle battery cooling. Afyren SAS serves diversified global markets such as human and animal nutrition, flavors and fragrances, life sciences, materials sciences, lubricants, and functional fluids, with target customers including manufacturers seeking decarbonization without altering production processes. Founded in 2012 and headquartered in Clermont-Ferrand, France, with additional facilities in Lyon and its first industrial plant AFYREN NEOXY—a joint venture with Bpifrance's SPI fund—located on the CHEMESIS platform in Carling Saint-Avold, the company operates primarily in Europe while pursuing projects in Thailand with a sugar industry leader and expanding in the Americas through distribution agreements. Recent developments include achieving continuous production at AFYREN NEOXY in June 2025, marking the start of industrial ramp-up with initial sales and plans for significant revenue in low single-digit millions of euros in 2025; securing €4 million in grants in July 2025 for AFYREN NEOXY and launching a performance-driven investment strategy; obtaining a €10 million CSR-indexed loan in January 2025 from a banking syndicate including BNP Paribas, Société Générale, and others to support ramp-up following a €9 million Prêt Nouvelle Industrie loan; and raising €23 million through a share capital increase in November 2025 to finance biorefinery optimization and expansion, alongside updating medium-term goals to build three plants generating €150 million in revenue at full capacity with 30% EBITDA margins.